Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Research Article


DOI :10.26650/IUITFD.1401786   IUP :10.26650/IUITFD.1401786    Full Text (PDF)

IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?

Rabia Deniz, Seda Karslı, Ömer Burak Ekinci, Ilkane Kalantarova, Alp Atasoy, Mustafa Önel, Ali Ağaçfidan, Filiz Akyüz, Kadir Demir, Fatih Beşışık, Sabahattin Kaymakoğlu

Objective: Unless treated, a hepatitis C virus (HCV) infection is associated with high morbidity and mortality. The study investigates anti-HCV screening efficacy and treatment access rates for patients.

Material and Method: This cross-sectional study screened all anti-HCV tests requested between January 2014-June 2017 from hospital records. Patient interviews were conducted by telephone-based interview.

Result: The overall number of anti-HCV tests requested was 77,783, 1,373 of which were positive. Among these, the study interviewed 488 patients (266 females, 222 males; mean age=52.81±16.5 years) and analyzed their tests. Further investigation with HCV-RNA had not been done in 69 (14.1%) anti-HCV positive patients. HCV-RNA was positive in 309 patients, 268 of whom were treated (86%), while 41 were not (14%). The main reasons for remaining untreated are: unknown (21%), no patient follow up (28%), or physician didn’t indicate (19%).

Conclusion: In order to successfully eliminate HCV, the anti-HCV test alone is not enough. Informing patients about the results of the anti-HCV test and, if positive, referring them for the HCV-RNA test are important. When considering the high amount of untreated patients, linkage to care should be encouraged in HCV-RNA positive patients unless an absolute contraindication is present.

Keywords: Hepatitis C virus infection, anti-HCV antibody, HCVRNA, screening
DOI :10.26650/IUITFD.1401786   IUP :10.26650/IUITFD.1401786    Full Text (PDF)

HEPATİT C TARAMASI İÇİN SADECE ANTİ-HCV TESTİ İSTEMEK YETERLİ MİDİR?

Rabia Deniz, Seda Karslı, Ömer Burak Ekinci, Ilkane Kalantarova, Alp Atasoy, Mustafa Önel, Ali Ağaçfidan, Filiz Akyüz, Kadir Demir, Fatih Beşışık, Sabahattin Kaymakoğlu

Amaç: HCV enfeksiyonu, tedavi edilmediği sürece yüksek morbidite ve mortalite ile ilişkilidir. Bu çalışmada anti-HCV tarama etkinliği ve tedaviye erişim oranları araştırılmıştır.

Gereç ve Yöntem: Bu kesitsel çalışmada Ocak 2014 ile Haziran 2017 tarihleri arasında istenen tüm anti-HCV testleri hastane kayıtlarından tarandı. Hasta görüşmeleri yüz yüze veya telefon ortamında yapıldı.

Bulgular: İstenilen toplam anti-HCV testi sayısı 77783 olup, bunların 1373'ü pozitif çıkmıştır. Bunlardan 266'sı kadın, 222'si erkek; yaş ortalaması 52,81±16,5 yıl olan 488 hastayla görüşme yapılmıştır. Anti-HCV pozitif hastaların 69'una (%14,1) HCV-RNA ile ileri araştırma yapılmadığı saptandı. 309 hastada HCV-RNA pozitifti ve 268'i tedavi almışken (%86), 41'i (%14) tedavi edilmemişti. Tedavisiz kalmanın temel nedenleri ise bilinmeyen (%21), takip edilmeyen hasta (%28) ve hekimin endikasyon göstermemesi (%19) olarak belirlendi.

Sonuç: HCV'nin başarılı bir şekilde eradike edilmesi için anti-anti-HCV testi tek başına yeterli değildir. Hastaların anti-HCV testi sonuçları hakkında bilgilendirilmesi; pozitif ise HCV-RNA testine başvurulması önemlidir. Tedavi edilmeyen hasta sayısının yüksek olduğu göz önüne alındığında, mutlak bir kontrendikasyon olmadığı sürece HCV-RNA pozitif hastalarda tedaviye yönlendirilme teşvik edilmelidir.

Keywords: Hepatit C enfeksiyonu, anti-HCV antikoru, HCV RNA, tarama

PDF View

References

  • Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl):S58-68. [CrossRef] google scholar
  • World Health Organization. Global hepatitis report 2017. Geneva SWhttps://www.who.int/publications/i/ item/9789241565455 . google scholar
  • Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146(5):1176-92. [CrossRef] google scholar
  • World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 28 Feb 19. http://apps.who. int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_ eng.pdf?ua=1. google scholar
  • Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20(1):249. [CrossRef] google scholar
  • Radwan D, Cachay E, Falade-Nwulia O, Moore R, Westergaard R, Mathews WC, et al. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80(5):559-67. [CrossRef] google scholar
  • Naz A, Mukry SN, Naseer I, Shamsi TS. Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pak J Med Sci 2018;34(5):1204-8. [CrossRef] google scholar
  • Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21(11):1020-6. [CrossRef] google scholar
  • Bielen R, Kremer C, Koc OM, Busschots D, Hendrickx D, Vanelderen P, et al. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39(4):667-75. [CrossRef] google scholar
  • Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? Epidemiol Infect 2015;143(13):2837-40. [CrossRef] google scholar
  • Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. Eur J Gastroenterol Hepatol 2016;28(11):1246-52. [CrossRef] google scholar
  • Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective-a qualitative exploration. Health Justice 2018;6(1):23. [CrossRef] google scholar
  • Buti M, Dominguez-Hernandez R, Casado MA, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13(11):e0208036. [CrossRef] google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Deniz, R., Karslı, S., Ekinci, Ö.B., Kalantarova, I., Atasoy, A., Önel, M., Ağaçfidan, A., Akyüz, F., Demir, K., Beşışık, F., & Kaymakoğlu, S. (2024). IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine, 87(3), 215-219. https://doi.org/10.26650/IUITFD.1401786


AMA

Deniz R, Karslı S, Ekinci Ö B, Kalantarova I, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine. 2024;87(3):215-219. https://doi.org/10.26650/IUITFD.1401786


ABNT

Deniz, R.; Karslı, S.; Ekinci, Ö.B.; Kalantarova, I.; Atasoy, A.; Önel, M.; Ağaçfidan, A.; Akyüz, F.; Demir, K.; Beşışık, F.; Kaymakoğlu, S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 87, n. 3, p. 215-219, 2024.


Chicago: Author-Date Style

Deniz, Rabia, and Seda Karslı and Ömer Burak Ekinci and Ilkane Kalantarova and Alp Atasoy and Mustafa Önel and Ali Ağaçfidan and Filiz Akyüz and Kadir Demir and Fatih Beşışık and Sabahattin Kaymakoğlu. 2024. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?.” Journal of Istanbul Faculty of Medicine 87, no. 3: 215-219. https://doi.org/10.26650/IUITFD.1401786


Chicago: Humanities Style

Deniz, Rabia, and Seda Karslı and Ömer Burak Ekinci and Ilkane Kalantarova and Alp Atasoy and Mustafa Önel and Ali Ağaçfidan and Filiz Akyüz and Kadir Demir and Fatih Beşışık and Sabahattin Kaymakoğlu. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?.” Journal of Istanbul Faculty of Medicine 87, no. 3 (Dec. 2024): 215-219. https://doi.org/10.26650/IUITFD.1401786


Harvard: Australian Style

Deniz, R & Karslı, S & Ekinci, ÖB & Kalantarova, I & Atasoy, A & Önel, M & Ağaçfidan, A & Akyüz, F & Demir, K & Beşışık, F & Kaymakoğlu, S 2024, 'IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?', Journal of Istanbul Faculty of Medicine, vol. 87, no. 3, pp. 215-219, viewed 23 Dec. 2024, https://doi.org/10.26650/IUITFD.1401786


Harvard: Author-Date Style

Deniz, R. and Karslı, S. and Ekinci, Ö.B. and Kalantarova, I. and Atasoy, A. and Önel, M. and Ağaçfidan, A. and Akyüz, F. and Demir, K. and Beşışık, F. and Kaymakoğlu, S. (2024) ‘IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?’, Journal of Istanbul Faculty of Medicine, 87(3), pp. 215-219. https://doi.org/10.26650/IUITFD.1401786 (23 Dec. 2024).


MLA

Deniz, Rabia, and Seda Karslı and Ömer Burak Ekinci and Ilkane Kalantarova and Alp Atasoy and Mustafa Önel and Ali Ağaçfidan and Filiz Akyüz and Kadir Demir and Fatih Beşışık and Sabahattin Kaymakoğlu. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?.” Journal of Istanbul Faculty of Medicine, vol. 87, no. 3, 2024, pp. 215-219. [Database Container], https://doi.org/10.26650/IUITFD.1401786


Vancouver

Deniz R, Karslı S, Ekinci ÖB, Kalantarova I, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine [Internet]. 23 Dec. 2024 [cited 23 Dec. 2024];87(3):215-219. Available from: https://doi.org/10.26650/IUITFD.1401786 doi: 10.26650/IUITFD.1401786


ISNAD

Deniz, Rabia - Karslı, Seda - Ekinci, ÖmerBurak - Kalantarova, Ilkane - Atasoy, Alp - Önel, Mustafa - Ağaçfidan, Ali - Akyüz, Filiz - Demir, Kadir - Beşışık, Fatih - Kaymakoğlu, Sabahattin. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?”. Journal of Istanbul Faculty of Medicine 87/3 (Dec. 2024): 215-219. https://doi.org/10.26650/IUITFD.1401786



TIMELINE


Submitted13.12.2023
Accepted22.03.2024
Published Online27.05.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.